Key Points
- Director Charles Mills bought 2,579,310 shares of Medline at an average price of $29 per share (~$74.8 million), leaving him with about 2.44 million shares—a large insider purchase signaling strong insider conviction.
- Medline recently completed its IPO, raising roughly $6.26 billion and enacting governance changes to support its transition to a public company.
- There was unusual options activity—approximately 20,689 put contracts (about a 326% increase vs. average)—which could indicate hedging or bearish bets and add near-term stock volatility.
Medline (NASDAQ:MDLN - Get Free Report) Director Charles Mills acquired 2,579,310 shares of Medline stock in a transaction dated Thursday, December 18th. The shares were acquired at an average cost of $29.00 per share, with a total value of $74,799,990.00. Following the completion of the acquisition, the director directly owned 2,441,379 shares in the company, valued at $70,799,991. This trade represents a -1,870.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.
Medline Stock Performance
Shares of Medline stock opened at $42.18 on Tuesday. Medline has a twelve month low of $34.89 and a twelve month high of $43.90.
Trending Headlines about Medline
Here are the key news stories impacting Medline this week:
- Positive Sentiment: Two Mills family directors made very large insider purchases (~2.58M shares each) at an average price of $29 per share on Dec. 18, signaling strong insider confidence; filings are available on the SEC site. Charles N. Mills filing Andrew J. Mills filing
- Positive Sentiment: Medline completed its IPO and announced governance changes intended to support public-company investor relations and oversight — a structural step that reduces execution risk as MDLN transitions to being a public company. Medline Completes IPO & Governance Changes
- Positive Sentiment: High-profile endorsement/comments: Jim Cramer publicly said he was “very impressed” with Medline’s IPO — positive media sentiment that can attract retail and institutional interest. Cramer on Medline IPO
- Neutral Sentiment: Medline’s IPO raised roughly $6.26 billion; coverage notes it was record-breaking for the company’s owners and generated a sizable payday for the Mills family — important context for capitalization and ownership but mixed for near-term float dynamics. Chicago Business: Mills family payday
- Neutral Sentiment: Medline is being featured on small-cap watchlists and market roundups, increasing visibility among retail and growth investors. AmericanBankingNews Dec 20 AmericanBankingNews Dec 19
- Negative Sentiment: Unusual options activity: traders bought ~20,689 put contracts (a ~326% increase vs. average), which can indicate short-term hedging or bearish bets that may add volatility to the stock. (Reported Dec. 22)
Medline Company Profile
(
Get Free Report)
Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.
In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
